Research and Markets: Hyperparathyroidism - Analysis and Market Forecasts to 2019

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9tjg2d/hyperparathyroidis) has announced the addition of GlobalData's new report "Hyperparathyroidism - Analysis and Market Forecasts to 2019" to their offering.

“Hyperparathyroidism - Analysis and Market Forecasts to 2019”

New Report Forecasts Hyperparathyroidism Therapeutics Market at $2.62 Billion by 2019

Hyperparathyroidism (HPT) patients can expect a slow but steady change in treatment options, as pharmaceutical companies work through stringent clinical trials, states a new report published by healthcare experts The authors.

The new report* looks at the drug pipeline and subsequent market forecasts for the endocrine disorder, which sees excessive amounts of the Parathyroid Hormone (PTH) produced from the parathyroid glands located in the lower neck.

Parathyroid glands respond to low calcium levels by increasing production of PTH, which controls calcium, phosphorus and vitamin D levels within the blood and bones. This reaction results in higher levels of calcium in the blood and urine, loss of calcium from bones and hypercalcemia.

According to the report, the hyperparathyroidism patient population is expected to increase over future years, primarily due to increasing Chronic Kidney Disease (CKD) prevalence and an increase in the elderly population.

Treatment options currently available for hyperparathyroidism can effectively control PTH levels, while offering moderate safety profiles, but a space still exists in the market for novel products with superior efficacy, lower adverse effects, improved patient compliance and increased affordability.

Significant opportunities still exist for novel molecules and novel formulations, and several new treatments are anticipated - including CTAP101 capsules, expected to be launched in the US in 2015, KAI-4169 IV in the US in 2016, and KAI-4169 IV in the EU5 (France, Germany, Italy, Spain, and the UK) in 2017.

The hyperparathyroidism therapeutics market is forecast to show moderate growth during the forecast period. The authors estimates the global hyperparathyroidism therapeutics market in 2011 at $2.01 billion, and expects it to grow at a Compound Annual Growth Rate (CAGR) of 3.3% to reach $2.62 billion by 2019.

Companies Mentioned

- Amgen Inc.

- Abbott Laboratories

- Cytochroma Inc.

- KAI Pharmaceuticals Inc.

For more information visit http://www.researchandmarkets.com/research/9tjg2d/hyperparathyroidis

Source: GlobalData